Galera Therapeutics, Inc. (GRTX)
USD 0.02
(8.11%)
USD 0.02
(8.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -46.95 Million USD | 8.35% |
| 2022 | -51.22 Million USD | 30.18% |
| 2021 | -73.36 Million USD | -3.99% |
| 2020 | -70.55 Million USD | -39.18% |
| 2019 | -50.69 Million USD | -108.99% |
| 2018 | -24.25 Million USD | -0.67% |
| 2017 | -24.09 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.2 Million USD | 8.04% |
| 2024 Q1 | -4.57 Million USD | 11.57% |
| 2023 Q3 | -13.39 Million USD | 20.3% |
| 2023 FY | -46.95 Million USD | 8.35% |
| 2023 Q4 | -5.17 Million USD | 61.36% |
| 2023 Q2 | -16.8 Million USD | -21.08% |
| 2023 Q1 | -13.88 Million USD | -5.49% |
| 2022 Q4 | -13.15 Million USD | -1.54% |
| 2022 Q2 | -11.95 Million USD | 9.12% |
| 2022 Q1 | -13.15 Million USD | 9.27% |
| 2022 FY | -51.22 Million USD | 30.18% |
| 2022 Q3 | -12.95 Million USD | -8.4% |
| 2021 Q2 | -21.08 Million USD | -20.63% |
| 2021 FY | -73.36 Million USD | -3.99% |
| 2021 Q3 | -20.3 Million USD | 3.74% |
| 2021 Q4 | -14.49 Million USD | 28.58% |
| 2021 Q1 | -17.48 Million USD | 7.72% |
| 2020 Q4 | -18.94 Million USD | -17.82% |
| 2020 FY | -70.55 Million USD | -39.18% |
| 2020 Q3 | -16.07 Million USD | 9.23% |
| 2020 Q2 | -17.71 Million USD | 0.59% |
| 2020 Q1 | -17.81 Million USD | -10.21% |
| 2019 Q1 | -10.39 Million USD | -17.36% |
| 2019 FY | -50.69 Million USD | -108.99% |
| 2019 Q4 | -16.16 Million USD | -25.76% |
| 2019 Q3 | -12.85 Million USD | -14.06% |
| 2019 Q2 | -11.27 Million USD | -8.42% |
| 2018 Q2 | -4.99 Million USD | 0.0% |
| 2018 Q1 | -4.99 Million USD | 0.0% |
| 2018 Q3 | -5.4 Million USD | -8.25% |
| 2018 FY | -24.25 Million USD | -0.67% |
| 2018 Q4 | -8.85 Million USD | -63.82% |
| 2017 FY | -24.09 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -9430.411% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -393.286% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -56.54% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 30.073% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -196.352% |
| Better Therapeutics, Inc. | -38.26 Million USD | -22.709% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -11.591% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -292.238% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -38.728% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -36.41% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 56.714% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -2230.882% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -38.083% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -3333.632% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -135.47% |
| Molecular Templates, Inc. | -10.46 Million USD | -348.605% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -234.15% |
| NexImmune, Inc. | -29.19 Million USD | -60.833% |
| Orgenesis Inc. | -53.63 Million USD | 12.464% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 8.467% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -60080.473% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -190.803% |
| Scopus BioPharma Inc. | -11.71 Million USD | -300.781% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 90.69% |
| Statera Biopharma, Inc. | -98.34 Million USD | 52.258% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -580.647% |
| Trevena, Inc. | -35.28 Million USD | -33.051% |
| Vaxxinity, Inc. | -58.28 Million USD | 19.446% |
| Vaccinex, Inc. | -22.88 Million USD | -105.161% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -4384.43% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 7.382% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -546.44% |